Formyl peptide receptor modulators: a patent review and potential applications for inflammatory diseases (2012-2015)

References

• von Andrian UH, Berger EM, Ramezani L, et al. In vivo behavior of neutrophils from two patients with distinct inherited leukocyte adhesion deficiency syndromes. J Clin Invest. 1993 Jun;91(6):2893–2897.
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Zychlinsky A. Neutrophil extracellular traps: is immunity the second function of chromatin? J Cell Biol. 2012 Sep 3;198(5):773–783.
   PubMed Web of Science ®Google Scholar
• Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 2013 Mar;13(3):159–175.
   PubMed Web of Science ®Google Scholar
• Kumar V, Sharma A. Neutrophils: Cinderella of innate immune system. Int Immunopharmacol. 2010 Nov;10(11):1325–1334.
   PubMed Web of Science ®Google Scholar
• Boulay F, Tardif M, Brouchon L, et al.. Synthesis and use of a novel N-formyl peptide derivative to isolate a human N-formyl peptide receptor Cdna. Biochem Bioph Res Co. 1990 May 16;168(3):1103–1109.
   PubMed Web of Science ®Google Scholar
• Hazeldine J, Hampson P, Lord JM. The impact of trauma on neutrophil function. Injury. 2014 Dec;45(12):1824–1833.
   PubMed Web of Science ®Google Scholar
• Le YY, Murphy PM, Wang JM. Formyl-peptide receptors revisited. Trends Immunol. 2002 Nov;23(11):541–548.
   PubMed Web of Science ®Google Scholar
• Lu B, Gerard NP, Eddy RL, et al. Mapping of genes for the human C5a receptor (C5AR), human FMLP receptor (FPR), and two FMLP receptor homologue orphan receptors (FPRH1, FPRH2) to chromosome 19.. Genomics. 1992 Jun;13(2):437–440.
   PubMed Web of Science ®Google Scholar
• Migeotte I, Communi D, Parmentier M. Formyl peptide receptors: a promiscuous subfamily of G protein-coupled receptors controlling immune responses. Cytokine Growth Factor Rev. 2006 Dec;17(6):501–519.
   PubMed Web of Science ®Google Scholar
• Sodin-Semrl S, Spagnolo A, Mikus R, et al. Opposing regulation of interleukin-8 and NF-kappaB responses by lipoxin A4 and serum amyloid A via the common lipoxin A receptor. Int J Immunopathol Pharmacol. 2004 May-Aug;17(2):145–156.
   PubMed Web of Science ®Google Scholar
• Kao W, Gu R, Jia Y, et al. A formyl peptide receptor agonist suppresses inflammation and bone damage in arthritis. Br J Pharmacol. 2014 Sep;171(17):4087–4096.
   PubMed Web of Science ®Google Scholar
• Schepetkin IA, Kirpotina LN, Khlebnikov AI, et al.. Antagonism of human formyl peptide receptor 1 (FPR1) by chromones and related isoflavones. Biochem Pharmacol. 2014 Dec 15;92(4):627–641.
   PubMed Web of Science ®Google Scholar
• Cevik-Aras H, Kalderén C, Jenmalm Jensen A, et al.. A non-peptide receptor inhibitor with selectivity for one of the neutrophil formyl peptide receptors, FPR 1. Biochem Pharmacol. 2012 Jun 15;83(12):1655–1662.
   PubMed Web of Science ®Google Scholar
• Stenfeldt A-L, Karlsson J, Wennerås C, et al. Cyclosporin H, Boc-MLF and Boc-FLFLF are antagonists that preferentially inhibit activity triggered through the formyl peptide receptor. Inflammation. 2007 Dec;30(6):224–229.
   PubMed Web of Science ®Google Scholar
• Thorén FB, Karlsson J, Dahlgren C, et al.. The anionic amphiphile SDS is an antagonist for the human neutrophil formyl peptide receptor 1. Biochem Pharmacol. 2010 Aug 1;80(3):389–395.
   PubMed Web of Science ®Google Scholar
• Unitt J, Fagura M, Phillips T, et al.. Discovery of small molecule human FPR1 receptor antagonists. Bioorg Med Chem Lett. 2011 May 15;21(10):2991–2997.
   PubMed Web of Science ®Google Scholar
• Liu MY, Zhao JH, Chen KQ, et al.. G protein-coupled receptor FPR1 as a pharmacologic target in inflammation and human glioblastoma. Int Immunopharmacol. 2012 Nov;14(3):283–288.
   PubMed Web of Science ®Google Scholar
• Cheng T-Y, Wu M-S, Lin J-T, et al. Formyl Peptide Receptor 1 Expression Is Associated with Tumor Progression and Survival in Gastric Cancer. Anticancer Res. 2014 May;34(5):2223–2229.
   PubMed Web of Science ®Google Scholar
• Dufton N, Perretti M. Therapeutic anti-inflammatory potential of formyl-peptide receptor agonists. Pharmacol Ther. 2010 Aug;127(2):175–188.
   PubMed Web of Science ®Google Scholar
• Tsai Y-F, Yu H-P, Chung P-J, et al. Osthol attenuates neutrophilic oxidative stress and hemorrhagic shock-induced lung injury via inhibition of phosphodiesterase 4. Free Radic Biol Med. 2015;89:387–400.
   PubMed Web of Science ®Google Scholar
• Ye RD, Boulay F, Wang JM, et al. International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the Formyl Peptide Receptor (FPR) Family. Pharmacol Rev. 2009 Jun;61(2):119–161.
   PubMed Web of Science ®Google Scholar
• Boulay F, Tardif M, Brouchon L, et al.. The human N-formylpeptide receptor. Characterization of two cDNA isolates and evidence for a new subfamily of G-protein-coupled receptors. Biochemistry. 1990 Dec 18;29(50):11123–11133.
   PubMed Web of Science ®Google Scholar
• Fu H, Karlsson J, Bylund J, et al. Ligand recognition and activation of formyl peptide receptors in neutrophils. J Leukoc Biol. 2006 Feb;79(2):247–256.
   PubMed Web of Science ®Google Scholar
• Ye RD, Cavanagh SL, Quehenberger O, et al.. Isolation of a cDNA that encodes a novel granulocyte N-formyl peptide receptor. Biochem Biophys Res Commun. 1992 Apr 30;184(2):582–589.
   PubMed Web of Science ®Google Scholar
• Carp H. Mitochondrial N-formylmethionyl proteins as chemoattractants for neutrophils. J Exp Med. 1982 Jan 1;155(1):264–275.
   PubMed Web of Science ®Google Scholar
• Dorward DA, Lucas CD, Chapman GB, et al. The role of formylated peptides and formyl peptide receptor 1 in governing neutrophil function during acute inflammation. Am J Pathol. 2015 May;185(5):1172–1184.
   PubMed Web of Science ®Google Scholar
• Schiffmann E, Corcoran BA, Wahl SM. N-formylmethionyl peptides as chemoattractants for leucocytes. Proc Natl Acad Sci U S A. 1975 Mar;72(3):1059–1062.
   PubMed Web of Science ®Google Scholar
• Panaro MA, Mitolo V. Cellular responses to FMLP challenging: a mini-review. Immunopharmacol Immunotoxicol. 1999 Aug;21(3):397–419.
   PubMed Web of Science ®Google Scholar
• Cattaneo F, Guerra G, Parisi M, et al. Expression of Formyl-peptide Receptors in Human Lung Carcinoma. Anticancer Res. 2015 May;35(5):2769–2774.
   PubMed Web of Science ®Google Scholar
• Huang J, Chen K, Huang J, et al. Regulation of the leucocyte chemoattractant receptor FPR in glioblastoma cells by cell differentiation. Carcinogenesis. 2009 Feb;30(2):348–355.
   PubMed Web of Science ®Google Scholar
• Zhan Y, Zhang H, Li J, et al. A novel biphenyl urea derivate inhibits the invasion of breast cancer through the modulation of CXCR4. J Cell Mol Med. 2015 Jul;19(7):1614–1623.
   PubMed Web of Science ®Google Scholar
• McDonald B. Intravascular danger signals guide neutrophils to sites of sterile inflammation (October, pg 362, 2010). Science. 2011 Mar 25;331(6024):1517–17.
   Web of Science ®Google Scholar
• Zhang Q, Raoof M, Chen Y, et al.. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010 Mar 4;464(7285):104–107.
   PubMed Web of Science ®Google Scholar
• Yang S-C, Hwang T-L. The potential impacts of formyl peptide receptor 1 in inflammatory diseases. Front Biosci (Elite Ed). 2016;8:436–449.
   PubMedGoogle Scholar
• Cattaneo F, Parisi M, Ammendola R. Distinct signaling cascades elicited by different formyl peptide receptor 2 (FPR2) agonists. Int J Mol Sci. 2013;14(4):7193–7230.
   PubMed Web of Science ®Google Scholar
• Vago JP, Nogueira CR, Tavares LP, et al. Annexin A1 modulates natural and glucocorticoid-induced resolution of inflammation by enhancing neutrophil apoptosis. J Leukoc Biol. 2012 Aug;92(2):249–258.
   PubMed Web of Science ®Google Scholar
• Ying G, Iribarren P, Zhou Y, et al.. Humanin, a newly identified neuroprotective factor, uses the G protein-coupled formylpeptide receptor-like-1 as a functional receptor. J Immunol. 2004 Jun 1;172(11):7078–7085.
   PubMed Web of Science ®Google Scholar
• Bozinovski S, Uddin M, Vlahos R, et al.. Serum amyloid A opposes lipoxin A₄ to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease.. Proc Natl Acad Sci U S A. 2012 Jan 17;109(3):935–940.
   PubMed Web of Science ®Google Scholar
• Le Y, Gong W, Tiffany HL, et al.. Amyloid (beta)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1. J Neurosci. 2001 Jan 15;21(2):RC123.
   PubMed Web of Science ®Google Scholar
• Resnati M, Pallavicini I, Wang JM, et al.. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1359–1364.
   PubMed Web of Science ®Google Scholar
• Devosse T, Dutoit R, Migeotte I, et al.. Processing of HEBP1 by Cathepsin D Gives Rise to F2L, the Agonist of Formyl Peptide Receptor 3. J Immunol. 2011 Aug 1;187(3):1475–1485.
   PubMed Web of Science ®Google Scholar
• Scapini P, Pereira S, Zhang H, et al. Multiple roles of Lyn kinase in myeloid cell signaling and function. Immunol Rev. 2009 Mar;228(1):23–40.
   PubMed Web of Science ®Google Scholar
• Mócsai A, Jakus Z, Vántus T, et al.. Kinase pathways in chemoattractant-induced degranulation of neutrophils: the role of p38 mitogen-activated protein kinase activated by Src family kinases. J Immunol. 2000 Apr 15;164(8):4321–4331.
   PubMed Web of Science ®Google Scholar
• Chen C-Y, Leu Y-L, Fang Y, et al. Anti-inflammatory effects of Perilla frutescens in activated human neutrophils through two independent pathways: Src family kinases and Calcium. Sci Rep. 2015;5:18204.
   PubMed Web of Science ®Google Scholar
• Yang S-C, Chung P-J, Ho C-M, et al.. Propofol inhibits superoxide production, elastase release, and chemotaxis in formyl peptide-activated human neutrophils by blocking formyl peptide receptor 1. J Immunol. 2013 Jun 15;190(12):6511–6519.
   PubMed Web of Science ®Google Scholar
• Yang S-C, Sung P-J, Lin C-F. Anti-inflammatory effects of secondary metabolites of marine Pseudomonas sp. in human neutrophils are through inhibiting P38 MAPK, JNK, and calcium pathways. PLoS One. 2014;9(12):e114761.
   PubMed Web of Science ®Google Scholar
• Selvatici R, Falzarano S, Mollica A, et al.. Signal transduction pathways triggered by selective formylpeptide analogues in human neutrophils. Eur J Pharmacol. 2006 Mar 18;534(1–3):1–11.
   PubMed Web of Science ®Google Scholar
• Spisani S, Pareschi MC, Buzzi M, et al. Effect of cyclic AMP level reduction on human neutrophil responses to formylated peptides. Cell Signal. 1996 Jun;8(4):269–277.
   PubMed Web of Science ®Google Scholar
• Crouser ED, Shao GH, Julian MW, et al. Monocyte activation by necrotic cells is promoted by mitochondrial proteins and formyl peptide receptors. Crit Care Med. 2009 Jun;37(6):2000–2009.
   PubMed Web of Science ®Google Scholar
• Wenceslau CF, McCarthy CG, Szasz T, et al. Mitochondrial N-formyl peptides induce cardiovascular collapse and sepsis-like syndrome. Am J Physiol Heart Circ Physiol. 2015 Apr 1;308(7):H768–77.
   PubMed Web of Science ®Google Scholar
• Wenceslau CF, Szasz T, McCarthy CG, et al. Mitochondrial N-formyl peptides cause airway contraction and lung neutrophil infiltration via formyl peptide receptor activation. Pulm Pharmacol Ther. 2016 Apr;37:49–56.
   PubMed Web of Science ®Google Scholar
• Stockley RA, Grant RA, Llewellyn-Jones CG, et al. Neutrophil formyl-peptide receptors. Relationship to peptide-induced responses and emphysema. Am J Respir Crit Care Med. 1994 Feb;149(2 Pt 1):464–468.
   PubMed Web of Science ®Google Scholar
• Planagumà A, Kazani S, Marigowda G, et al.. Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. Am J Respir Crit Care Med. 2008 Sep 15;178(6):574–582.
   PubMed Web of Science ®Google Scholar
• Bleyl JU, Heller AR, Fehrenbach A, et al. Pretreatment with perfluorohexane vapor attenuates fMLP-induced lung injury in isolated perfused rabbit lungs. Exp Lung Res. 2010 Aug;36(6):342–351.
   PubMed Web of Science ®Google Scholar
• Schiffmann E, Showell HV, Corcoran BA, et al. The isolation and partial characterization of neutrophil chemotactic factors from Escherichia coli. J Immunol. 1975 Jun;114(6):1831–1837.
   PubMed Web of Science ®Google Scholar
• Rabiet M-J, Huet E, Boulay F. Human mitochondria-derived N-formylated peptides are novel agonists equally active on FPR and FPRL1, while Listeria monocytogenes-derived peptides preferentially activate FPR. Eur J Immunol. 2005 Aug;35(8):2486–2495.
   PubMed Web of Science ®Google Scholar
• Grommes J, Drechsler M, Soehnlein O. CCR5 and FPR1 mediate neutrophil recruitment in endotoxin-induced lung injury. J Innate Immun. 2014;6(1):111–116.
   PubMed Web of Science ®Google Scholar
• Wentworth CC, Jones RM, Kwon YM, et al. Commensal-epithelial signaling mediated via formyl peptide receptors. Am J Pathol. 2010 Dec;177(6):2782–2790.
   PubMed Web of Science ®Google Scholar
• Babbin BA, Jesaitis AJ, Ivanov AI, et al.. Formyl peptide receptor-1 activation enhances intestinal epithelial cell restitution through phosphatidylinositol 3-kinase-dependent activation of Rac1 and Cdc42. J Immunol. 2007 Dec 15;179(12):8112–8121.
   PubMed Web of Science ®Google Scholar
• Ledesma de Paolo MI, Celener Gravelle P, De Paula JA, et al. Stimulation of inflammatory mediators secretion by chemotactic peptides in rat colitis model. Acta Gastroenterol Latinoam. 1996;26(1):23–30.
   PubMedGoogle Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002 Dec 26; 420(6917):860–867.
   PubMed Web of Science ®Google Scholar
• Le Y, Hu J, Gong W, et al.. Expression of functional formyl peptide receptors by human astrocytoma cell lines. J Neuroimmunol. 2000 Nov 1;111(1–2):102–108.
   PubMed Web of Science ®Google Scholar
• Margareto J, Leis O, Larrarte E, et al. Gene expression profiling of human gliomas reveals differences between GBM and LGA related to energy metabolism and notch signaling pathways. J Mol Neurosci. 2007;32(1):53–63.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Bian X, Le Y, et al.. Formylpeptide receptor FPR and the rapid growth of malignant human gliomas. J Natl Cancer Inst. 2005 Jun 1;97(11):823–835.
   PubMedGoogle Scholar
• Chen KD, Liu MY, Liu Y, et al. Formylpeptide receptor-2 contributes to colonic epithelial homeostasis, inflammation, and tumorigenesis. J Clin Investig. 2013 Apr;123(4):1694–1704.
   PubMed Web of Science ®Google Scholar
• Prevete N, Liotti F, Visciano C, et al. The formyl peptide receptor 1 exerts a tumor suppressor function in human gastric cancer by inhibiting angiogenesis. Oncogene. 2015 Jul;34(29):3826–3838.
   PubMed Web of Science ®Google Scholar
• Fredman G, Oh SF, Ayilavarapu S, et al. Impaired phagocytosis in localized aggressive periodontitis: rescue by Resolvin E1. PLoS One. 2011;6(9):e24422.
   PubMed Web of Science ®Google Scholar
• Maney P, Walters JD. Formylpeptide receptor single nucleotide polymorphism 348T>C and its relationship to polymorphonuclear leukocyte chemotaxis in aggressive periodontitis.. J Periodontol. 2009 Sep;80(9):1498–1505.
   PubMed Web of Science ®Google Scholar
• Jepsen K, Jepsen S. Antibiotics/antimicrobials: systemic and local administration in the therapy of mild to moderately advanced periodontitis. Periodontol 2000. 2016 Jun;71(1):82–112.
   PubMed Web of Science ®Google Scholar
• Goldman RC, Frost DJ, Capobianco JO, et al. Antifungal drug targets: Candida secreted aspartyl protease and fungal wall beta-glucan synthesis. Infect Agents Dis. 1995 Dec;4(4):228–247.
   PubMedGoogle Scholar
• Heasley BH, Pacofsky GJ, Mamai A, et al.. Synthesis and biological evaluation of antifungal derivatives of enfumafungin as orally bioavailable inhibitors of β-1,3-glucan synthase.. Bioorg Med Chem Lett. 2012 Nov 15;22(22):6811–6816.
   PubMed Web of Science ®Google Scholar
• Forrest KM, Judice JK, Warren HS, et al. Compositions and methods for the treatment of fungal infections. WO2015035102A2. 2015.
   Google Scholar
• Judice JK, Forrest K, Warren HS, et al. Compositions and methods for the treatment of fungal infections. WO2015164289A1. 2015.
   Google Scholar
• Thongyoo P, Bonomelli C, Leatherbarrow RJ, et al.. Potent inhibitors of beta-tryptase and human leukocyte elastase based on the MCoTI-II scaffold. J Med Chem. 2009 Oct 22;52(20):6197–6200.
   PubMed Web of Science ®Google Scholar
• Jung F, Obrecht D, Löwe R, et al. Template -fixed peptidomimetics as inhibitors of fpr1. EP2764010A1. 2014.
   Google Scholar
• Benson JD Antagonism of human formyl peptide receptor for treatment of disease. US20120231994A1. 2012.
   Google Scholar
• Cardini S, Dalli J, Fineschi S, et al. Genetic ablation of the fpr1 gene confers protection from smoking-induced lung emphysema in mice. Am J Respir Cell Mol Biol. 2012 Sep;47(3):332–339.
   PubMed Web of Science ®Google Scholar
• Rittner HL, Hackel D, Voigt P, et al.. Mycobacteria attenuate nociceptive responses by formyl peptide receptor triggered opioid peptide release from neutrophils. PLoS Pathog. 2009 Apr;5(4):e1000362.
   PubMed Web of Science ®Google Scholar
• Hwang TL, Hsieh PW, Huang YT, et al. FPR1 antagonist derivatives and use thereof. US20150099691. 2015.
   Google Scholar
• Beard RL, Donello JE, Garst ME, et al. Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity. WO2012074785A1. 2012.
   Google Scholar
• Beard RL, Donello JE, Duong TT, et al. Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators. WO2012109544A1. 2012.
   Google Scholar
• Lehmann SV, Hoeck U, Breinholdt J, et al. Characterization and chemistry of imidazolidinyl urea and diazolidinyl urea. Contact Dermatitis. 2006 Jan;54(1):50–58.
   PubMed Web of Science ®Google Scholar
• Beard RL, Vuligonda V, Th VU, et al. 2,5-dioxoimidazolidin-1-yl-3-urea derivatives as formyl peptide modulators. WO2015116566A1. 2015.
   Google Scholar
• Beard RL, Vuligonda V, Vu T, et al. 2,5-dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (fprl-1) receptor modulators. EP2776403A1. 2014.
   Google Scholar
• Cui J, Ding M, Deng W, et al.. Discovery of bis-aryl urea derivatives as potent and selective Limk inhibitors: Exploring Limk1 activity and Limk1/ROCK2 selectivity through a combined computational study. Bioorg Med Chem. 2015 Dec 1;23(23):7464–7477.
   PubMed Web of Science ®Google Scholar
• Ravez S, Arsenlis S, Barczyk A, et al.. Synthesis and biological evaluation of di-aryl urea derivatives as c-Kit inhibitors. Bioorg Med Chem. 2015 Nov 15;23(22):7340–7347.
   PubMed Web of Science ®Google Scholar
• Beard RL, Duong TT, Donello JE, et al. Aryl urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators. WO2013070600A1. 2013.
   Google Scholar
• Sun D, Lee RE. Solid-phase synthesis of a thymidinyl dipeptide urea library. J Comb Chem. 2007 May-Jun;9(3):370–385.
   PubMedGoogle Scholar
• Beard RL, Duong TT, Garst ME Diphenyl urea derivatives as formyl peptide receptor modulators. WO2015042071A1. 2015.
   Google Scholar
• Obiol-Pardo C, Alcarraz-Vizán G, Cascante M, et al. Diphenyl urea derivatives as inhibitors of transketolase: a structure-based virtual screening. PLoS One. 2012;7(3):e32276.
   PubMed Web of Science ®Google Scholar
• Bur D, Corminboeuf O, Cren S, et al. Bridged spiro [2.4] heptane derivatives as alx receptor and/or fprl2 agonists. WO2010134014A1. 2010.
   Google Scholar
• Kim S-Y, Park HB, Cho J-H, et al.. Synthesis and antibacterial activities of novel oxazolidinones having spiro[2,4]heptane moieties. Bioorg Med Chem Lett. 2009 May 1;19(9):2558–2561.
   PubMed Web of Science ®Google Scholar
• Park HB, Jo NH, Hong JH, et al. Synthesis and in-vitro activity of novel 1beta-methylcarbapenems having spiro[2,4]heptane moieties. Arch Pharm (Weinheim). 2007 Oct;340(10):530–537.
   PubMed Web of Science ®Google Scholar
• Corminboeuf O, Pozzi D Fluorinated bridged spiro[2.4]heptane derivatives as alx receptor agonists. WO2013171694A1. 2013.
   Google Scholar
• Corminboeuf O, Cren S 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists. EP2850058A1. 2015.
   Google Scholar
• Corminboeuf O, Cren S, Pozzi D Difluoroethyl-oxazole substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists. WO2014206966A1. 2014.
   Google Scholar
• Corminboeuf O, Cren S, Pozzi D Piperazine substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists. WO2015007830A1. 2015.
   Google Scholar
• Bur D, Corminboeuf O, Cren S, et al. Bridged spiro[2.4]heptane ester derivatives. WO2012066488A2. 2012.
   Google Scholar
• Devkota L, Lin C-M, Strecker TE, et al.. Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents. Bioorg Med Chem. 2016 Mar 1;24(5):938–956.
   PubMed Web of Science ®Google Scholar
• Beard RL, Donello JE, Garst ME, et al. Dihydronaphthalene and naphthalene derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators. WO2012125305A1. 2012.
   Google Scholar
• Ai Q, Ge P, Dai J, et al.. The catalase inhibitor aminotriazole alleviates acute alcoholic liver injury. Sheng Li Xue Bao. 2015 Feb 25;67(1):97–102.
   PubMedGoogle Scholar
• Lee JN, Kim S-G, Lim J-Y, et al. 3-Aminotriazole protects from CoCl2-induced ototoxicity by inhibiting the generation of reactive oxygen species and proinflammatory cytokines in mice. Arch Toxicol. 2016 Apr;90(4):781–791.
   PubMed Web of Science ®Google Scholar
• Bur D, Corminboeuf O, Cren S, et al. Hydroxylated aminotriazole derivatives as alx receptor agonists. WO2012077051A1. 2012.
   Google Scholar
• Bur D, Corminboeuf O, Cren S, et al. Aminotriazole derivatives as alx agonists. WO2009077990A1. 2009.
   Google Scholar
• Bur D, Corminboeuf O, Cren S, et al. Fluorinated aminotriazole derivatives. US8580831B2. 2013.
   Google Scholar
• Shahwar D, Tahir MN, Mughal MS, et al. Phenyl N-phenylcarbamate. Acta Crystallogr E. 2009;65:o1363.
   Google Scholar
• Gooyit M, Song W, Mahasenan KV, et al.. O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier. J Med Chem. 2013 Oct 24;56(20):8139–8150.
   PubMed Web of Science ®Google Scholar
• Beard RL, Duong TT, Garst ME Phenylcarbamate derivatives as formyl peptide receptor modulators. WO2015077451A1. 2015.
   Google Scholar
• Beard RL, Vuligonda V, Vu T, et al. Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators. WO2013009543A1. 2013.
   Google Scholar
• Byrtus H, Obniska J, Czopek A, et al.. Synthesis and anticonvulsant activity of new N-Mannich bases derived from 5-cyclopropyl-5-phenyl- and 5-cyclopropyl-5-(4-chlorophenyl)-imidazolidine-2,4-diones. Bioorg Med Chem. 2011 Oct 15;19(20):6149–6156.
   PubMed Web of Science ®Google Scholar
• Czopek A, Sałat K, Byrtus H, et al.. Antinociceptive activity of novel amide derivatives of imidazolidine-2,4-dione in a mouse model of acute pain. Pharmacol Rep. 2016 Jan 11;68(3):529–535.
   PubMedGoogle Scholar
• Beard RL, Vuligonda V, Donello JE, et al. Imidazolidine-2,4-dione derivatives as n-formyl peptide receptor 2 modulators. WO2013122953A1. 2013.
   Google Scholar
• Beard RL, Duong TT, Donello JE, et al. (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators. EP2838887A1. 2015.
   Google Scholar
• Beard RL, Duong TT, Donello JE, et al. Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators. WO2015009545A1. 2015.
   Google Scholar
• Beard RL, Duong TT, Donello JE, et al. Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators. EP2770989A1. 2014.
   Google Scholar
• Bur D, Corminboeuf O, Cren S, et al. Oxazolyl-methylether derivatives as alx receptor agonists. WO2012077049A1. 2012.
   Google Scholar
• Bur D, Corminboeuf O, Cren S, et al. Oxazole and thiazole derivatives as alx receptor agonists. EP2440536A1. 2012.
   Google Scholar
• Haag T, Grossbach D, Winter G, et al. Crystalline potassium salt of lipoxin a4 analogs. CN101553456B. 2013.
   Google Scholar
• Terakado M, Hirobe M, Iwahashi M, et al. Alxr agonist compound. WO2015005305A1. 2015.
   Google Scholar
• Pieretti S, Di Giannuario A, De Felice M, et al. Stimulus-dependent specificity for annexin 1 inhibition of the inflammatory nociceptive response: the involvement of the receptor for formylated peptides. Pain. 2004 May;109(1–2):52–63.
   PubMed Web of Science ®Google Scholar
• Colli S, Colombo S, Tremoli E, et al. Effects of tenoxicam on superoxide anion formation, beta-glucuronidase release and fMLP binding in human neutrophils: comparison with other NSAIDs. Pharmacol Res. 1991 May;23(4):367–379.
   PubMed Web of Science ®Google Scholar
• Stenfeldt A-L, Karlsson J, Wennerås C, et al. The non-steroidal anti-inflammatory drug piroxicam blocks ligand binding to the formyl peptide receptor but not the formyl peptide receptor like 1. Biochem Pharmacol. 2007 Oct 1;74(7):1050–1056.
   PubMed Web of Science ®Google Scholar
• Krajčová A, Waldauf P, Anděl M, et al. Propofol infusion syndrome: a structured review of experimental studies and 153 published case reports. Crit Care. 2015;19:398.
   PubMed Web of Science ®Google Scholar